Zejula-Avastin Combo Treating Advanced Cancer Patients in Phase 2 Trial

Zejula-Avastin Combo Treating Advanced Cancer Patients in Phase 2 Trial
Zejula (niraparib) given in combination with Avastin (bevacizumab) shows promising safety and efficacy at delaying disease progression in women with advanced ovarian cancer who had responded to a first-line platinum-based chemotherapy plus Avastin, interim results from a Phase 2 trial show. These findings are in the presentation, “Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab,” for the May 14 webinar as part of the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer. The meeting, set for March in Toronto, was canceled due to the COVID-19 pandemic. Avastin, developed by Genentech (part of the Roche Group), belongs to a class of medications known as anti-angiogenic therapies. It works by stoppin
Subscribe or to access all post and page content.